
Gerald Illerhaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2399088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncology, The, 2016, 17, 1697-1708.	10.7	532
2	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
3	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	1.4	429
4	Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer. JAMA Oncology, 2017, 3, 1237.	7.1	296
5	High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma. Journal of Clinical Oncology, 2006, 24, 3865-3870.	1.6	272
6	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
7	High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica, 2008, 93, 147-148.	3.5	189
8	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology,the, 2016, 3, e388-e397.	4.6	128
9	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). BMC Cancer, 2016, 16, 282.	2.6	53
10	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Advances, 2020, 4, 3378-3381.	5.2	34
11	Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 2018, 132, 681-688.	1.4	23
12	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer, 2019, 19, 287.	2.6	22
13	High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Primary CNS Lymphoma: Updated Results from a Pilot and Phase II Study. Blood, 2008, 112, 3594-3594.	1.4	17
14	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	2.8	9
15	Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review. Cancers, 2021, 13, 4268.	3.7	9
16	A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. Leukemia and Lymphoma, 2019, 60, 334-340.	1.3	7
17	Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteinsâ€: Journal of Immunology, 2015, 195, 4549-4550.	0.8	5
18	PCNSL: biomarker better than biopsy?. Blood, 2011, 117, 2987-2989.	1.4	2

GERALD ILLERHAUS

#	Article	IF	CITATIONS
19	CNS relapse in DLBCL: a calculable risk?. Blood, 2021, 137, 1011-1012.	1.4	2
20	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. Blood, 2014, 124, 74-74.	1.4	2
21	Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis. Blood, 2011, 118, 3089-3089.	1.4	1
22	Primary CNS lymphoma and secondary involvement of the central nervous system. Memo - Magazine of European Medical Oncology, 2009, 2, 146-149.	0.5	0
23	Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy Blood, 2009, 114, 4766-4766.	1.4	0
24	Therapeutic Granulocyte Transfusions in Neutropenic Patients with Invasive Pulmonary Aspergillosis,. Blood, 2011, 118, 3372-3372.	1.4	0